Full Year Results 2000

Full Year Results 2000 'Profit before tax up 16 per cent; EPS up 18 per cent' Financial Highlights (before Exceptional Items) Group Full Full Constan (Continuing operations*) Year Year t 2000 1999 Currenc $m $m y % Sales 15,804 15,134 +8 Operating Profit 3,984 3,570 +14 Profit before Tax 4,110 3,556 +16 Earnings per Share Group $1.64 $1.41 +18 Group (Statutory FRS3) $1.44 $0.64 * Excluding Specialties and Agrochemicals from both periods All narrative in this section refers to growth rates at constant exchange rates (CER) * Sales up 8 per cent; US Pharmaceuticals up 12 per cent * Operating profit up 14 per cent; EPS up 18 per cent * Strength of US Dollar reduced reported sales by 4 per cent and operating profit by 2 per cent * Important growth products up 50 per cent; Life cycle initiatives fuel ® ® ® ® ® growth of Atacand , Casodex , Arimidex , Zomig , and Seroquel * Continued good progress with the new product pipeline, with fourteen high quality candidate drugs nominated for development, ahead of target * The statutory accounts for the Group include the results of Specialties through 30 June 1999, and for Agrochemicals through 13 November 2000. Including the results of these discontinued operations the Group had reported sales of $18,103 million ($18,445 million in 1999), operating profit (pre exceptional items) of $4,330 million ($3,908 million in 1999), and EPS of $1.44 ($0.64 in 1999) Tom McKillop, Chief Executive Officer, said: "Significant progress was made last year. Following the demerger of Agrochemicals, we became one of the most focused pharmaceutical companies in the industry; AstraZeneca is operating successfully as a single unified global organisation, and our exciting R&D pipeline made strong progress. These are important achievements which give us confidence that we will deliver sustained growth in shareholder value." AstraZeneca PLC Fourth Quarter Results 2000 Financial Highlights (before Exceptional Items) Group 4th 4th Constan (Continuing operations*) Quarter Quarter t 2000 1999 Currenc $m $m y % Sales 4,144 3,916 +13 Operating Profit 971 796 +22 Profit before Tax 1,034 802 +23 Earnings per Share Group $0.42 $0.32 +25 Group (Statutory FRS3) $0.19 $(0.10) * Excluding Specialties and Agrochemicals from both periods All narrative in this section refers to growth rates at constant exchange rates (CER) * Sales up 13 per cent; US Pharmaceuticals up 22 per cent * Operating profit up 22 per cent * EPS up 25 per cent * Strength of US Dollar reduced reported sales by 7 per cent and operating profit by 1 per cent * The statutory accounts for the Group include the results of Agrochemicals through 13 November 2000. Including the results of these discontinued operations the Group had reported sales of $4,265 million ($4,493 million in 1999), operating profit (pre exceptional items) of $965 million ($789 million in 1999), and EPS of $0.19 ($(0.10) in 1999). London, 8 February 2001 ------------------------------------------------------------ This information was brought to you by BIT http://www.bit.se The following files are available for download: http://www.bit.se/bitonline/2001/02/08/20010208BIT00050/bit0001.doc The full year-end report http://www.bit.se/bitonline/2001/02/08/20010208BIT00050/bit0002.pdf The full year-end report

About Us

AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialisation of prescription medicines. As a leader in gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease medicines, AstraZeneca generated global revenues of US $32.8 billion in 2009. For more information please visit: www.astrazeneca.com

Subscribe